US 7468379
Inhibition of osteolytic lesions by SRC kinase inhibitors
granted A61KA61K31/44A61K31/47
Quick answer
US patent 7468379 (Inhibition of osteolytic lesions by SRC kinase inhibitors) held by The Board of Regents of the University of Texas System expires Mon Dec 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Dec 23 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K31/44, A61K31/47, A61K31/4709, A61K31/496